Antiinflammatory effects of long-acting β2-agonists in patients with asthma: A systematic review and metaanalysis

Chest

Volumn 136, Issue 1, 2009, Pages 145-154

  Sindi, Anees ^a   Todd, David C ^a   Nair, Parameswaran ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; INTERLEUKIN 4; NITRIC OXIDE; PLACEBO; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS BIOPSY; CELL ACTIVATION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG EFFECT; DRUG POTENTIATION; EOSINOPHIL; EXHALATION; HUMAN; INFLAMMATORY CELL; LUNG LAVAGE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPUTUM ANALYSIS; SYSTEMATIC REVIEW;

EID: 67650841304     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2149     Document Type: Article

References (58)

1. Becker A, Lemiere C, Berube D, et al. Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003. Can Med Assoc J 2005; 173(suppl):S3-S11
2. Maddox L, Schwarz DA. The pathophysiology of asthma. Annu Rev Med 2002; 53:477-498
3. British Thoracic Society. British guideline on the management of asthma. Thorax 2003;58(suppl):i1-i94
4. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics; 2002. J Allergy Clin Immunol 2002; 110(suppl):S141-S219
5. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit that montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120:423-430
6. Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective that fluticasone plus oral montelukast in asthma. Respir Med 2003; 97:234-241
7. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised comparative trial. BMJ 2003; 327:891
8. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320:1368-1373
9. Remington TL, DiGiovine B. Long-acting B-agonists: antiinflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2004; 11:74-78
10. Sindi A, Todd DC, Nair P. Anti-inflammatory effect of long acting β agonists in patients with asthma: a systematic review [abstract]. Am J Respir Crit Care Med 2007; 175:A691
11. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12
12. Fuglsang G, Vikre-Jorgensen J, Agertoft L, et al. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol 1998; 25:314-321
13. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150:1006-1011
14. Kraft M, Wenzel SE, Bettinger CM, et al. The effects of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997; 111:1249-1254
15. Jeffery PK, Venge P, Gizycki MJ, et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20:1378-1385
16. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001; 285:2583-2593
17. Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting β(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir 0Crit Care Med 1999; 160:1493-1499
18. Lindqvist A, Karjalainen E, Laitinen L, et al. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol 2003; 112:23-28
19. Lipworth BJ, Dempsey OJ, Aziz I, et al. Effects of adding a leukotriene antagonist or a long-acting β2-agonist in asthmatic patients with the glycine-16 β2-adrenoceptor genotype. Am J Med 2000; 109:114-121
20. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128:1936-1942
21. Prieto L, Gutierrez V, Torres V, et al. Effects of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects. Chest 2002; 122:798-805
22. Ramage L, Cree I, Dhilon P. Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels. Int Arch Allergy Immunol 1994; 105:181-184
23. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003; 21:994-999
24. Roberts JA, Bradding P, Britten KM, et al. The long-acting β2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14:275-282
25. Stelmach I, Grzelewski T, Majak P, et al. Effect of triamcinolone, montelukast, and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma [in Polish]. Pol Merkur Lekarski 2001; 11:247-251
26. Stelmach I, Gorski P, Jerzyńska J, et al. A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children. Ann Allergy Asthma Immunol 2002; 89:67-73
27. Stelmach I, Jerzyńska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and β-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 2002; 32:264-269
28. Stelmach I, Jerzyńska J, Majak P, et al. The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on serum levels of siCAM-1, sIL-2R in serum and clinical course of asthma in children [in Polish]. Pol Merkur Lekarski 2002; 12:99-103
29. Stelmach I, Grzelewski T, Stelmach W, et al. Effect of triamcinolone acetonide, montelukast, nedocromil sodium, and formoterol on eosinophilic blood counts, ECP serum levels and clinical parameters in children with asthma [in Polish]. Pol Merkur Lekarski 2002; 12:208-213
30. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J 1998; 54:261-268
31. Wallin A, Sandstrom T, Soderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999; 159:79-86
32. Wallin A, Sandstrom T, Cioppa GD, et al. The effects of regular inhaled formoterol and budesonide on performed Th-2 cytokines in mild asthmatics. Respir Med 2002; 96: 1021-1025
33. Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118:1049-1058
34. Buchvald F, Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 2003; 91:309-313
35. Currie GP, Stenback S, Lipworth BJ. Effects of fluticasone vs. fluticasone/salmeterol on airway caliber and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003; 56:11-17
36. Currie GP, Bates CE, Lee DK, et al. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003; 59:11-15
37. Green RH, Brightling CE, McKenna S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J 2006; 27:1144-1151
38. Hueck C, Heickendorff, Wolthers OD. A randomized controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child 2000; 83:334-339
39. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001
40. Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006; 61:306-312
41. Overbeek S, Mulder PG, Baelemans SM, et al. Formoterol added to low-dose budesonide has no additional anti-inflammatory effect in asthmatic patients. Chest 2005; 128:1121-1127
42. Prieto L, Gutierrez V, Perez-Frances C, et al. Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. Ann Allergy Asthma Immunol 2005; 95:452-461
43. Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 2003; 112:72-78
44. Parameswaran K, Fanat A, O'Byrne PM. Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. Allergy 2006; 61:731-736
45. Giembycz MA, Kaur M, Leigh R, et al. A Holy Grail of asthma management: toward understanding how long-acting β(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008; 153:1090 -1104
46. Kaur M, Chivers JE, Giembycz MA, et al. Long-acting β2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 2008; 73:203-214
47. Seeto LJ, Johnson M, Hendel N, et al. Effect of dexamethasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD) [abstract]. Am J Respir Crit Care Med 2002; 165:A597
48. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274:1005-1010
49. Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and β-2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293-1299
50. Tool AT, Mul FP, Knol EF, et al. The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. Eur Respir J 1996; 22:141s-145s
51. Mohede IC, Van Ark I, Brons FM, et al. Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells. Int J Immunopharmacol 1996; 18:193-201
52. American Thoracic, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005; 171: 912-930
53. O'Conner TM, Kelly MM, Leigh R, et al. Additional antiinflammatory effects of inhaled budesonide/formoterol over inhaled budesonide in subjects with atopic asthma [abstract]. Eur Respir J 2006; 28:441s
54. Kelly M, O'Connor T, Leigh R, et al. Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myofibroblasts [abstract]. Eur Respir J 2007; 30:137s
55. Orsida BE, Ward C, Li X, et al. Effect of a long-acting β2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001; 164:117-121
56. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-494
57. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721
58. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178:1009-1016